Search research articles
Contact Us
Filters
Showing results (381-390 of 403) with videos related to
Page
of 41
Sort By:
Biorxiv : the Preprint Server for Biology
|
October 9, 2023
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer
Na Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
BMC Cancer
|
April 16, 2020
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
Hai-Bo Sun, Wen-Qun Xing, Xian-Ben Liu, et al.
Plos Medicine
|
July 21, 2010
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma
Jeran K Stratford, David J Bentrem, Judy M Anderson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 12, 2009
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J Creighton, Xiaoxian Li, Melissa Landis, et al.
Cell Reports
|
October 18, 2018
Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast
Yeji An, Jessica R Adams, Daniel P Hollern, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 4, 2026
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer
Frederick M Howard, Anran Li, Sara Kochanny, et al.
Nature
|
January 10, 2024
MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis
Min-Guk Cho, Rashmi J Kumar, Chien-Chu Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2018
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Maki Tanioka, Cheng Fan, Joel S Parker, et al.
Genes & Development
|
July 4, 2014
Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase
Xingnan Zheng, Bo Zhai, Peppi Koivunen, et al.
Cancer Research
|
May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics
Bryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.
Page
of 41
Search research articles
Search
Showing results (381-390 of 403) with videos related to
Sort By:
Page
of 41
Biorxiv : the Preprint Server for Biology
|
October 9, 2023
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer
Na Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
BMC Cancer
|
April 16, 2020
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
Hai-Bo Sun, Wen-Qun Xing, Xian-Ben Liu, et al.
Plos Medicine
|
July 21, 2010
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma
Jeran K Stratford, David J Bentrem, Judy M Anderson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 12, 2009
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J Creighton, Xiaoxian Li, Melissa Landis, et al.
Cell Reports
|
October 18, 2018
Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast
Yeji An, Jessica R Adams, Daniel P Hollern, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 4, 2026
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer
Frederick M Howard, Anran Li, Sara Kochanny, et al.
Nature
|
January 10, 2024
MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis
Min-Guk Cho, Rashmi J Kumar, Chien-Chu Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2018
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Maki Tanioka, Cheng Fan, Joel S Parker, et al.
Genes & Development
|
July 4, 2014
Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase
Xingnan Zheng, Bo Zhai, Peppi Koivunen, et al.
Cancer Research
|
May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics
Bryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.
Page
of 41